Narcolepsy clinical trials at UCSF

1 research study open to eligible people

Showing trials for

  • ALKS 2680 in Subjects With Narcolepsy Type 2

    open to eligible people ages 18-70

    The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.

    San Francisco, California and other locations

Last updated: